ATE345800T1 - Pten-hemmer oder maxi-k-kanalöffner - Google Patents
Pten-hemmer oder maxi-k-kanalöffnerInfo
- Publication number
- ATE345800T1 ATE345800T1 AT04713984T AT04713984T ATE345800T1 AT E345800 T1 ATE345800 T1 AT E345800T1 AT 04713984 T AT04713984 T AT 04713984T AT 04713984 T AT04713984 T AT 04713984T AT E345800 T1 ATE345800 T1 AT E345800T1
- Authority
- AT
- Austria
- Prior art keywords
- maxi
- channel opener
- pten inhibitor
- pten
- inhibitor
- Prior art date
Links
- 102000016469 Large-Conductance Calcium-Activated Potassium Channels Human genes 0.000 title 1
- 108010092555 Large-Conductance Calcium-Activated Potassium Channels Proteins 0.000 title 1
- 229940123940 PTEN inhibitor Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44943503P | 2003-02-25 | 2003-02-25 | |
| US44958903P | 2003-02-26 | 2003-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE345800T1 true ATE345800T1 (de) | 2006-12-15 |
Family
ID=32930512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04713984T ATE345800T1 (de) | 2003-02-25 | 2004-02-24 | Pten-hemmer oder maxi-k-kanalöffner |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US7825130B2 (enExample) |
| EP (1) | EP1599205B1 (enExample) |
| JP (3) | JP4590397B2 (enExample) |
| KR (1) | KR101031163B1 (enExample) |
| CN (2) | CN1780623B (enExample) |
| AR (1) | AR043379A1 (enExample) |
| AT (1) | ATE345800T1 (enExample) |
| AU (1) | AU2004216340B9 (enExample) |
| BR (1) | BRPI0407832A (enExample) |
| CA (1) | CA2515590C (enExample) |
| CY (1) | CY1106294T1 (enExample) |
| DE (1) | DE602004003348T2 (enExample) |
| DK (1) | DK1599205T3 (enExample) |
| ES (1) | ES2276282T3 (enExample) |
| MX (1) | MXPA05008996A (enExample) |
| MY (1) | MY136863A (enExample) |
| PT (1) | PT1599205E (enExample) |
| TW (1) | TWI323660B (enExample) |
| WO (1) | WO2004075897A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI323660B (en) * | 2003-02-25 | 2010-04-21 | Otsuka Pharma Co Ltd | Pten inhibitor or maxi-k channels opener |
| TW200848041A (en) * | 2007-03-30 | 2008-12-16 | Otsuka Pharma Co Ltd | A medicament for treating schizophrenia comprising cilostazol |
| TWI489983B (zh) * | 2007-05-22 | 2015-07-01 | Otsuka Pharma Co Ltd | 用於治療阿茲海默症之藥劑 |
| AR067746A1 (es) * | 2007-08-02 | 2009-10-21 | Otsuka Pharma Co Ltd | Un medicamento para tratar glaucoma que comprende como elemento activo compuesto de ciclodextrina - clatrato de cilostazol |
| KR101639820B1 (ko) | 2008-01-17 | 2016-07-14 | 쿠이 류 | 난소 여포의 체외 성숙 방법 |
| AR070816A1 (es) * | 2008-03-14 | 2010-05-05 | Otsuka Pharma Co Ltd | Farmaco de combinacion para tratar trastornos vasculares |
| US20110189308A1 (en) * | 2008-03-17 | 2011-08-04 | Asa Abeliovich | Methods to treat neurodegenerative conditions or diseases by targeting components of a pten signaling pathway |
| CA2724199C (en) * | 2008-06-06 | 2016-07-26 | Children's Medical Center Corporation | Promoting axon regeneration in the adult cns through control of protein translation |
| EP2488637B1 (en) * | 2009-10-16 | 2015-12-23 | The University Of British Columbia | Inhibitors of phosphatase and tensin homolog (pten) compositions, uses and methods |
| EP2322163A1 (en) * | 2009-11-03 | 2011-05-18 | Pharnext | New therapeutics approaches for treating alzheimer disease |
| CA2854225A1 (en) | 2011-11-01 | 2013-05-10 | Children's Medical Center Corporation | Co-activation of mtor and stat3 pathways to promote neuronal survival and regeneration |
| KR20150027800A (ko) * | 2012-06-15 | 2015-03-12 | 고에키 자이단 호징 센탄 이료 신코 자이단 | 경도 인지 장해의 예방 및/또는 치료제 |
| JP2016040542A (ja) * | 2014-08-13 | 2016-03-24 | 学校法人金沢医科大学 | 認知症治療薬または認知症治療薬候補物質のスクリーニング方法 |
| JP2017070404A (ja) * | 2015-10-06 | 2017-04-13 | アンディ チャオ | トイレ床面の清潔な芳香パッド |
| KR102181657B1 (ko) * | 2016-05-19 | 2020-11-23 | 고쿠리츠켄큐카이하츠호진 고쿠리츠쥰칸키뵤 겐큐센터 | 치매의 예방 및/또는 치료를 위한 약물 |
| US20230270737A1 (en) * | 2020-05-11 | 2023-08-31 | Shimadzu Corporation | Therapeutic Agent for Mild Cognitive Impairment |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5535019A (en) * | 1978-09-01 | 1980-03-11 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
| JPS5649378A (en) * | 1979-08-25 | 1981-05-02 | Otsuka Pharmaceut Co Ltd | Tetrazolylalkoxycarbostyril derivative |
| JPH0653666B2 (ja) | 1990-10-22 | 1994-07-20 | 大塚製薬株式会社 | ヒトの糖尿病性知覚障害および末梢神経障害の治療剤 |
| JPH0614444A (ja) * | 1992-06-25 | 1994-01-21 | Central Japan Railway Co | 電力ケーブル接続部の固定装置 |
| JPH06239745A (ja) * | 1992-12-24 | 1994-08-30 | Otsuka Pharmaceut Co Ltd | 乾癬治療剤 |
| WO1994014444A1 (fr) * | 1992-12-24 | 1994-07-07 | Otsuka Pharmaceutical Co., Ltd. | Remede contre le psoriasis |
| JPH0776584A (ja) | 1993-09-07 | 1995-03-20 | Otsuka Pharmaceut Co Ltd | 内皮細胞障害抑制剤 |
| JP3944257B2 (ja) | 1995-12-07 | 2007-07-11 | 大塚製薬株式会社 | 肝実質細胞増殖因子産生増加剤 |
| US6322525B1 (en) * | 1997-08-28 | 2001-11-27 | Visco Technologies, Inc. | Method of analyzing data from a circulating blood viscometer for determining absolute and effective blood viscosity |
| US6428488B1 (en) * | 1997-08-28 | 2002-08-06 | Kenneth Kensey | Dual riser/dual capillary viscometer for newtonian and non-newtonian fluids |
| US6019735A (en) * | 1997-08-28 | 2000-02-01 | Visco Technologies, Inc. | Viscosity measuring apparatus and method of use |
| US6322524B1 (en) * | 1997-08-28 | 2001-11-27 | Visco Technologies, Inc. | Dual riser/single capillary viscometer |
| JP2002537231A (ja) * | 1998-05-01 | 2002-11-05 | カトラー,ニール,アール | 特定の患者群における性的機能障害の治療 |
| US6187790B1 (en) * | 1999-03-04 | 2001-02-13 | Neal R. Cutler | Use of cilostazol for treatment of sexual dysfunction |
| US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6257985B1 (en) * | 1999-10-01 | 2001-07-10 | Rexnord Corporation | Global shaft coupling |
| US6484565B2 (en) * | 1999-11-12 | 2002-11-26 | Drexel University | Single riser/single capillary viscometer using mass detection or column height detection |
| JP4159224B2 (ja) | 2000-02-29 | 2008-10-01 | 三洋電機株式会社 | 食器洗浄機 |
| US6458804B1 (en) | 2001-01-26 | 2002-10-01 | R.T. Alamo Venturesi, Llc | Methods for the treatment of central nervous system disorders in certain patient groups |
| US6743806B2 (en) * | 2002-10-23 | 2004-06-01 | Otsuka Pharmaceutical Company, Limited | Active oxygen scavenger |
| TWI323660B (en) * | 2003-02-25 | 2010-04-21 | Otsuka Pharma Co Ltd | Pten inhibitor or maxi-k channels opener |
-
2004
- 2004-02-11 TW TW093103143A patent/TWI323660B/zh not_active IP Right Cessation
- 2004-02-17 MY MYPI20040511A patent/MY136863A/en unknown
- 2004-02-24 DK DK04713984T patent/DK1599205T3/da active
- 2004-02-24 US US10/546,632 patent/US7825130B2/en not_active Expired - Fee Related
- 2004-02-24 KR KR1020057015646A patent/KR101031163B1/ko not_active Expired - Fee Related
- 2004-02-24 BR BRPI0407832-2A patent/BRPI0407832A/pt not_active IP Right Cessation
- 2004-02-24 AU AU2004216340A patent/AU2004216340B9/en not_active Ceased
- 2004-02-24 CN CN2004800111403A patent/CN1780623B/zh not_active Expired - Fee Related
- 2004-02-24 WO PCT/JP2004/002146 patent/WO2004075897A1/en not_active Ceased
- 2004-02-24 CA CA2515590A patent/CA2515590C/en not_active Expired - Fee Related
- 2004-02-24 AT AT04713984T patent/ATE345800T1/de active
- 2004-02-24 JP JP2006502683A patent/JP4590397B2/ja not_active Expired - Fee Related
- 2004-02-24 PT PT04713984T patent/PT1599205E/pt unknown
- 2004-02-24 ES ES04713984T patent/ES2276282T3/es not_active Expired - Lifetime
- 2004-02-24 AR ARP040100573A patent/AR043379A1/es unknown
- 2004-02-24 CN CN201010130082.3A patent/CN101829116B/zh not_active Expired - Fee Related
- 2004-02-24 EP EP04713984A patent/EP1599205B1/en not_active Expired - Lifetime
- 2004-02-24 DE DE602004003348T patent/DE602004003348T2/de not_active Expired - Lifetime
- 2004-02-24 MX MXPA05008996A patent/MXPA05008996A/es active IP Right Grant
-
2006
- 2006-12-19 CY CY20061101814T patent/CY1106294T1/el unknown
-
2009
- 2009-12-30 US US12/650,275 patent/US8329731B2/en not_active Expired - Fee Related
-
2010
- 2010-08-12 JP JP2010180661A patent/JP5208172B2/ja not_active Expired - Lifetime
-
2012
- 2012-11-07 US US13/671,448 patent/US8653104B2/en not_active Expired - Fee Related
-
2013
- 2013-01-10 JP JP2013002314A patent/JP5566482B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2016001I1 (no) | Trastuzumab emtansin | |
| NO20054852D0 (no) | GFAT inhibitorer | |
| ATE480436T1 (de) | Schiebetritt | |
| DE602004018837D1 (de) | Ptidase-iv-inhibitoren | |
| NO20043645L (no) | Sykloalkylinhibitorer av kaliumkanal-funksjon | |
| FR2845095B1 (fr) | Piece coulissante | |
| ATE345800T1 (de) | Pten-hemmer oder maxi-k-kanalöffner | |
| FI20031590L (fi) | Kuljetin | |
| FR2837194B1 (fr) | Tire-bouchon | |
| FI20031037L (fi) | Purennanohjain | |
| NO20044269L (no) | Smamolekylaere inntrengningsinhibitorer | |
| FI20031679L (fi) | Työnnin | |
| DE60303539D1 (de) | Kurvenförderer | |
| FI20031591L (fi) | Kuljetin | |
| DE502004001560D1 (de) | Kaltarbeitsstahl-Gegenstand | |
| EP1776355A4 (en) | POTASSIUM CHANNEL INHIBITORS | |
| DE60307471D1 (de) | Hemmung | |
| SE0302642L (sv) | Bullerskydd | |
| GB0325331D0 (en) | Gate | |
| SE0300858L (sv) | Tröskelramp | |
| AU2003227952A8 (en) | Metalloproteinase inhibitors | |
| SI1599205T1 (sl) | PTEN inhibitor ali sredstvo za odpiranje Maxi-K kanalov | |
| SE0301349D0 (sv) | Fingerrings-kapsylöppnare | |
| FIU20020489U0 (fi) | Sormus - pullonavaaja | |
| ATE295930T1 (de) | Schiebetor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1599205 Country of ref document: EP |